EveliQure Biotechnologies
PrivateLast Round
Strategic
Mar 20, 2026
Total Funding Raised
$34M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
EveliQure Biotechnologies operates in Healthcare & Life Sciences and is based in Vienna. Its latest recorded funding round was a Grant round in September 2020.
EveliQure Biotechnologies is a clinical-stage biotechnology company that develops innovative vaccine technology platforms to prevent diarrheal diseases caused by enteric pathogens such as Shigella and ETEC.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EveliQure Biotechnologies Comparables
Compare EveliQure Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Scandinavian Biopharma | 87% | |
| Eli Lilly and Company | 82% | |
| MecVax | 79% |
For institutional investors. Book with your work email.
EveliQure Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Mar 20, 2026 | ||||
| Grant | Sep 9, 2020 | ||||
| VC Round | Jul 2, 2020 | ||||
| Grant | Nov 5, 2019 | ||||
| Grant | Sep 10, 2019 | ||||
Grant | Jan 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
EveliQure Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ARAX Capital Partners | VC Round |
| National Institute of Allergy and Infectious Diseases | Grant |
| Austria Wirtschaftsservice | Grant |
| FFG Austrian Research Promotion Agency | Grant |
| Wellcome Trust | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 44% MoM.
- Mar 20, 2026
Serum Institute of India led the strategic round.
For institutional investors. Book with your work email.
EveliQure Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EveliQure Biotechnologies's valuation, stock price, and market status.
Is EveliQure Biotechnologies a public or private company?
EveliQure Biotechnologies is a private company.
What is the current stock price of EveliQure Biotechnologies?
EveliQure Biotechnologies is a private company, so its shares have no public market price. Caplight tracks EveliQure Biotechnologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EveliQure Biotechnologies worth (valuation)?
Valuation information for EveliQure Biotechnologies is not publicly available.
Can I buy EveliQure Biotechnologies stock?
EveliQure Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EveliQure Biotechnologies's last funding round?
EveliQure Biotechnologies's most recent funding round was Strategic on March 20, 2026.
Who are the main investors in EveliQure Biotechnologies?
Key investors in EveliQure Biotechnologies include ARAX Capital Partners, National Institute of Allergy and Infectious Diseases, Austria Wirtschaftsservice, FFG Austrian Research Promotion Agency, Wellcome Trust.
Will EveliQure Biotechnologies IPO soon?
No public IPO plans have been announced for EveliQure Biotechnologies.
How can I track EveliQure Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades in EveliQure Biotechnologies's shares on secondary markets.